Business
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\nOTTAWA, April 29, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.\n The Joint-Venture will synergize the capabilities of the two companies: Products:  The companies have identified product candidates in the fields of pain, oncology and ophthalmology, addressing a total market size of over $10BN. (Source: MedTrack™) New Routes of Administration: Altus’ SmartCelle™ insoluble drug delivery platform enables intravenous, topical, intra-nasal and oral delivery. Smartcelle’s™ proven ability to enhance the solubility of cannabinoids permits increased oral absorption and enables low volume parenteral and transmucosal delivery.  Intellitab™ and Flexitab™ technologies will deliver Safer to Use™ products to patients.  New Intellectual Property:  Altus’ distinct drug delivery technologies provide Tetra with significant strategic advantages over the competition and will enable Tetra to significantly improve some of the current products under development. In addition to SmartCelle™ these include Intellitab™ abuse deterrent technology platform and, Flexitab™ breakable sustained release tablet technology for enhanced dosing flexibility.  All platforms are protected by patents enforced globally. Commercial Development, Manufacturing and Supply.  Combining Altus and Tetra capabilities ensures these essential parts of the value chain are addressed early and efficiently. Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are extremely excited about finalizing this agreement which will enable us to improve existing products and will allow us to exploit a  number of different delivery mechanisms including Intra-Nasal, Intravenous and Oral Sustained Release Tablets.   Furthermore, Altus’ technology will play a key role in strengthening Tetra’s Intellectual Property for its product portfolio.  This newly created joint-venture will also serve to benefit our p...